Figure 4.

Induction of B-cell memory to each of the four DENV serotypes in a subset of 18 high-dose cohort subjects who received 3 injections of study product (vaccine/placebo).

Blood samples to assess B-cell memory were collected at 2 time points (at Study Month 0 immediately before the first injection, and at Study Month 3 [28 days Postdose 3]) in 18 high-dose cohort participants: 5 recipients of V180 with 30 ISCO™ units of ISCOMATRIX™ adjuvant, 5 recipients of V180 with 60 ISCO™ units of ISCOMATRIX™ adjuvant, 5 recipients of unadjuvanted V180, and 3 placebo recipients.Panel A: Change in Proportion of Dengue-specific memory B cells from Study Month 0 (prevaccination baseline) to Study Month 3 (28 days Postdose 3)Note: Each line represents the data for 1 participantPanel B: Dengue-specific memory B cell frequencies at Study Month 3 (28 days Postdose 3)Note: ASC = antibody secreting cells